The interactions of atorvastatin and fluvastatin with carbamazepine, phenytoin and valproate in the mouse maximal electroshock seizure model

European Journal of Pharmacology

Volumn 674, Issue 1, 2011, Pages 20-26

  Stepien, Karolina M ^a,b   Tomaszewski, Michal ^a   Luszczki, Jarogniew J ^a,c   Czuczwar, Stanislaw J ^a,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Antiepileptic drug; Atorvastatin; Carbamazepine; Chimney test; Fluvastatin; Passive avoidance task; Phenytoin; Seizure; Valproate magnesium

Indexed keywords

ATORVASTATIN; CARBAMAZEPINE; FLUINDOSTATIN; PHENYTOIN; VALPROATE MAGNESIUM; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG INHIBITION; DRUG POTENTIATION; ELECTRIC SHOCK; FLUORESCENCE POLARIZATION IMMUNOASSAY; LONG TERM MEMORY; MALE; MEMORY DISORDER; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; SEIZURE; SINGLE DRUG DOSE; TASK PERFORMANCE;

ANIMALS; ANTICONVULSANTS; BRAIN; CARBAMAZEPINE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ELECTROSHOCK; FATTY ACIDS, MONOUNSATURATED; HEPTANOIC ACIDS; INDOLES; MALE; MEMORY; MICE; MOTOR ACTIVITY; PHENYTOIN; PYRROLES; SEIZURES; VALPROIC ACID;

EID: 82255195993     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.10.030     Document Type: Article

References (41)

1. S. Appel, T. Rufenacht, G. Kalafsky, W. Tetzloff, Z. Kallay, G. Hitzenberger, and K. Kutz Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus Am. J. Cardiol. 76 1995 29A 32A
2. S. Bellosta, R. Paoletti, and A. Corsini Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 109 2004 III-50 III-57
3. J.R. Boissier, J. Tardy, and J.C. Diverres Une nouvelle méthode simple pour explorer l'action tranquilisante: Le test de la cheminée Med. Exp. (Basel) 3 1960 81 84
4. J. Bösel, F. Gandor, C. Harms, M. Synowitz, U. Harms, P.C. Djoufack, D. Megow, U. Dirnagl, H. Hortnagl, K.B. Fink, and M. Endres Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones J. Neurochem. 92 2005 1386 1398 (Pubitemid 40389208)
5. M.J. Brodie, S.D. Shorvon, R. Canger, P. Halasz, S. Johannessen, P. Thompson, H.G. Wieser, and P. Wolf Commission on European affairs: appropriate standards of epilepsy care across Europe Epilepsia 38 1997 1245 1250 (Pubitemid 27481426)
6. S.D. Candrilli, R. Manjunath, K.L. Davis, and B.E. Gidal The association between antiepileptic drugs and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy Epilepsy Res. 91 2010 260 266
7. D.D. Cilia, L.R. Whitfiled, D.M. Gibson, A.J. Sedman, and E.L. Posvar Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastation, an inhibitor of HMG-CoA reductase, in healthy subjects Clin. Pharmacol. Ther. 60 1996 687 695 (Pubitemid 27025917)
8. P. Cleary, S. Shorvon, and R. Tallis Late onset seizures as a predictor of subsequent stroke Lancet 363 2004 1184 1186 (Pubitemid 38481843)
9. A. Corsini, S. Bellosta, R. Baetta, R. Fumagalli, R. Paoletti, and F. Bernini New insight into the pharmacodynamic and pharmacokinetic properties of statins Pharmacol. Ther. 84 1999 413 428
10. S.S. Egger, J. Drewe, and R.G. Schlienger Potential drug-drug interactions in the medication of medical patients at hospital discharge Eur. J. Clin. Pharmacol. 58 2003 773 778 (Pubitemid 36399235)
11. M. Endres, and U. Laufs Effects of statins on endothelium and signalling mechanisms Stroke 35 2004 2708 2711 (Pubitemid 39458376)
12. M. Etminan, A. Samii, and J.M. Brophy Statin use and risk of epilepsy Neurology 75 2010 1496 1500
13. B.E. Gidal, J.A. French, P. Grossman, and G. LeTeuff Assessment of potential drug interactions in patients with epilepsy. Impact of age and sex Neurology 72 2009 419 425
14. L.B. Goldstein, P. Amarenco, M. Lamonte, S. Gilbert, M. Messig, A. Callahan, M. Hennerici, H. Sillesen, K.M. Welch, and S.P.A.R.C.L. Investigators Relative effect of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study Stroke 39 2008 2444 2448
15. C.W. Holtzman, B.S. Wiggins, and S.A. Spinler Role of p-glycoprotein in statin drug interactions Pharmacotherapy 26 2006 1601 1607 (Pubitemid 44704473)
16. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri, and D.A. Drachman Statins and the risk of dementia Lancet 356 2000 1627 1631
17. B. Kwak, F. Mulhaupt, S. Myit, and F. Mach Statins as a newly recognized type of immunomodulator Nat. Med. 6 2000 1399 1402 (Pubitemid 32001026)
18. P. Kwan, and M.J. Brodie Early identification of refractory epilepsy N. Engl. J. Med. 342 2000 314 319 (Pubitemid 30075244)
19. J.K. Lee, J.S. Won, A.K. Singh, and I. Singh Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death Neurosci. Lett. 440 2008 260 264
20. J.T. Litchfield, and F. Wilcoxon A simplified method of evaluating dose-effect experiments J. Pharmacol. Exp. 96 1949 99 113
21. J.J. Luszczki, K. Glowniak, and S.J. Czuczwar Imperatorin enhances the protective activity of conventional antiepileptic drugs against maximal electroshock-induced seizures in mice Eur. J. Clin. Pharmacol. 574 2007 133 139 (Pubitemid 47575522)
22. J.M. Miller, J.N. Bullman, S. Alexander, and K.E. VanLandingham A prospective assessment of the effect of phenytoin on the pharmacokinetics of atorvastatin Epilepsia 49 2008 444
23. M.J. Murphy, and M.H. Dominiczak Efficacy of statin therapy: possible effect of phenytoin Postgrad. Med. J. 75 1998 359 361
24. N.S. Naval, M.A. Mirski, and J.R. Carhuapoma Impact of statins on validation of ICH mortality prediction models Neurol. Res. 31 2009 425 429
25. P.J. Neuvonen, J.T. Backman, and M. Niemi Pharmacokinetic comparison of the potential over-the-conter statins simvastatin, lovastatin, fluvastatin and pravastatin Clin. Pharmacokinet. 47 2008 463 474 (Pubitemid 351861958)
26. E. Park, A.A. Velumian, and A.G. Fehlings The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration J. Neurotrauma 21 2004 754 774 (Pubitemid 38880247)
27. P.N. Patsalos, W. Fröscher, F. Pisani, and C.M. vanRijn The importance of drug interactions in epilepsy therapy Epilepsia 43 2002 365 385 (Pubitemid 34297175)
28. E.L. Posvar, L.L. Radulovic, D.D. Cilia, L.R. Whitfield, and A.J. Dedman Tolerance and pharmacokinetics of single-dose atorvastatin, a potential inhibitor of HMG-CoA reductase, in healthy subjects J. Clin. Pharmacol. 36 1996 728 731 (Pubitemid 26295777)
29. A.E. Ratz Bravo, L. Tchambaz, A. Krahenbuhl-Mechler, L. Hess, R.G. Schlieger, and S. Krahenbuhl Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy Drug Saf. 28 2005 263 275 (Pubitemid 40364892)
30. A. Saheki, T. Terasaki, I. Tamai, and A. Tsuji In vitro and in vivo blood brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (MG-CoA) reductase inhibitors Pharm. Res. 11 1994 305 311 (Pubitemid 24076229)
31. R.D. Scheyer, J.A. Cramer, and R.H. Mattson A pharmacodynamic approach to the estimate of carbamazepine autoinduction J. Pharm. Sci. 84 1994 491 494 (Pubitemid 24222369)
32. C.D. Scripture, and J.A. Pieper Clinical pharmacokinetics of fluvastatin Clin. Pharmacokinet. 40 2001 263 281 (Pubitemid 32458153)
33. Y. Shitara, and Y. Sugiyama Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions Pharmacol. Ther. 112 2006 71 105 (Pubitemid 44301483)
34. S. Sierra, M.C. Ramos, P. Molina, J.A. Vazquez, and J.S. Burgos Statins as neuroprotectants: A comparative in vivo study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death J. Alzheimers Dis. 23 2011 307 318
35. C. Smaldone, S. Brugaletta, V. Pazzano, and G. Liuzzo Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors Cardiovasc. Hematol. Agents Med. Chem. 7 2009 279 294
36. K.M. Tan, J.G. Kelly, and K. McGarry Statins and phenytoin interact-a case history Br. J. Clin. Pharmacol. 65 2007 147 148
37. M. Ucar, M. Neuvonen, H. Luurila, R. Dahlqvist, P.J. Neuvonen, and T. Mjorndal Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid Eur. J. Clin. Pharmacol. 59 2004 879 882 (Pubitemid 38333678)
38. P. Venault, G. Chapouthier, L.P. deCarvalho, J. Simiand, M. Morre, R.H. Dodd, and J. Rossier Benzodiazepine impairs and beta-carboline enhances performance in learning and memory task Nature 321 1986 864 866 (Pubitemid 16097728)
39. A. Vezzani, and T. Granata Brain inflammation in epilepsy: experimental and clinical evidence Epilepsia 46 2005 1724 1743 (Pubitemid 44921957)
40. D. Williams, and J. Feely Pharmacokinetic-pharmadynamic drug interactions with HMG-CoA reductase inhibitors Clin. Pharmacokinet. 41 2002 343 370 (Pubitemid 34713089)
41. B. Wolozin, W. Kellman, P. Ruosseau, G.G. Celesia, and G. Siegel Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors Arch. Neurol. 57 2000 1439 1443